by Mark Curtis | Nov 20, 2014
. You have all by now heard that Dendreon has filed for bankruptcy protection. If you’re a regular reader of Signals, you may have first heard the news here. While the company has successfully reached agreements on a financial restructuring with a majority of its...
by David Brindley | Nov 19, 2014
. With contributions from James Smith, a recent Oxford University graduate and current CASMI Translational Stem Cell Consortium Research Associate. Both the IBC Cell Therapy Bioprocessing (ICTB) conference and the Stem Cells and Regenerative Medicine Congress...
by Stacey Johnson | Nov 14, 2014
. The month of November can mean different things to different people. For example, Canadians recognize Remembrance Day on November 11, Americans have Veterans Day and my Polish friends celebrate National Independence Day. There’s American Thanksgiving immediately...
by David Brindley | Nov 13, 2014
. With contributions from James Smith, a recent Oxford University graduate and current CASMI Translational Stem Cell Consortium Research Associate In the early 1770s, Britain faced a significant financial dilemma. One of its most important commercial institutions,...
by Mark Curtis | Nov 10, 2014
. I had the pleasure of meeting Dr. Eytan Abraham over lunch on the first day of the Till & McCulloch Meetings, held last month in Ottawa (October 27-29). After some discussion about cell therapy manufacturing, I learned that he is the new Head of Research and...
by Mark Curtis | Nov 4, 2014
. Those following the regenerative medicine (RM) industry are likely in-tune with a rapidly evolving market, on the periphery, that is shaping up to provide a very attractive value proposition to patients, industry, and investors alike. The health care industry is...
Comments